Redx Pharma PLC (AIM:REDX)'s Lisa Anson speaks to Proactive as collaboration with Jazz Pharmaceuticals triggers a US$5mln milestone payment to Redx, with clinical work now expected to get underway.
Anson provides investors with key insights as Jazz achieved investigational new drug status with US regulators for JZP815, which was originally discovered by Redx.
Anson also talks about the £34.3mln equity raise announced earlier this month, with the firm issuing 58mln new shares priced at 59p each through the placing.